Pharmacokinetic study of voriconazole in immunocompromised children aged 2 to <12 years
- Registry ID
- EUCTR2012-001133-14
- Source registry
- EUCTR
- Phase
- PHASE2
- Sponsor
- Pfizer Inc. 235 East 42nd Street, New York, NY 10017
- Last update
- 2026-08-16
Conditions
- Invasive fungal infections
Summary
To characterize the pharmacokinetics of voriconazole following an intravenous (IV) to oral switch regimen in immunocompromised children aged 2 to <12 years who are at high risk for systemic fungal infection.
View on source registry